宋明明

[摘要] 目的 探究3种不同剂型的二甲双胍治疗糖尿病的成本-效果。方法 2017年2—10月间将该科210例糖尿病患者进行随机分组为A、B、C 3组，各为70例；A组：用吡格列酮二甲双胍普通片治疗；B组：二甲双胍缓释片治疗；C组：用二甲双胍肠溶片治疗。治疗后，比较3组的药物成本和临床效果。结果 治疗后3组患者的FBG、PBG以及HbA1c指标差异无统计学意义（P>0.05）。而对比治疗前后差异有统计学意义（P<0.05）。A组的成本-效果明显优于B、C组，而B、C组则差异无统计学意义（P>0.05）。结论 3种不同剂型的二甲双胍均可用来治疗糖尿病，从成本-效果方面来考量的话，二甲双胍普通片则明显优于其他两种剂型。

[关键词] 不同剂型；二甲双胍；糖尿病；成本-效果

[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2018）03（a）-0081-02

[Abstract] Objective To study the comparison of cost-effect of three types of different doses of melbine in treatment of diabetes. Methods 210 cases of diabetes patients in our department from February to October 2017 were randomly divided into three groups with 70 cases in each， the group A were treated with pioglitazone metformin common tablets， the group B were treated with metformin hydrochloride sustained-release tablets， while the group C were treated with metformin enteric coated tablets， after treatment， the cost of drugs and clinical effect were compared between the three groups. Results After treatment， the differences in the FBG， PBG and HbA1c between the three groups were not statistically significant（P>0.05）， and the difference before and after treatment was statistically significants（P<0.05）， and the cost-effect in the group A was obviously better than that in the group B and in the group C， but the difference between the group B and group C was not statistically significant（P>0.05）. Conclusion Three types of different doses can be used to treat the diabetes， but in terms of cost-effect， the effect of metformin common tablets is obviously better than that of the other two types.

[Key words] Different types； Melbine； Diabetes； Cost-effect

糖尿病已经成为一种需要终生治疗的内科常见病以及多发病[1]。其主要是由胰岛素抵抗下降，且胰岛素分泌不足。近年来随着发病率的增高，糖尿病的治疗成本也引发了人们的普遍关注，当下甲双胍能极好的增强胰岛素作用，能很好地达到降低血糖[2]。不同剂型的二甲双胍糖尿病的治疗存在一定的差异性，如效果、成本等。2017年2—10月间对该科收住的患者采用3种不同剂型的二甲双胍进行治疗，用FBG、PBG、HbA1c指标以及成本-效果的方面进行评价[3]。以便为临床用药提供有价值的参考，现报道如下。

1 资料与方法

1.1 一般资料

在该院收住的糖尿病患者210例，均符合糖尿病临床诊断的标准。女性患者93例，男性患者117例；患者年龄在39～73岁之间，平均年龄（56.0±5.0）岁；将上述患者随机分为各70例的A、B、C组，比较3组患者性别和年龄等资料，3组患者的一般资料差异无统计学意义（P>0.05），具有一定的可比性。